Enveric Biosciences Inc.

0.1820-0.0181-9.05%Vol 1.34M1Y Perf -90.52%
Jun 24th, 2022 16:00 DELAYED
BID0.1820 ASK0.2069
Open0.2000 Previous Close0.2001
Pre-Market- After-Market0.19
 - -  0.01 4.40%
Target Price
0.65 
Analyst Rating
Moderate Buy 1.67
Potential %
257.14 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★★★     66.10
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★★★     60.28
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
0.34 
Earnings Rating
Market Cap9.59M 
Earnings Date
12th Aug 2022
Alpha-0.11 Standard Deviation0.25
Beta1.78 

Today's Price Range

0.18200.2200

52W Range

0.17003.74

5 Year PE Ratio Range

-6.40-0.6000

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-2.31%
1 Month
-10.21%
3 Months
-50.29%
6 Months
-82.99%
1 Year
-90.52%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
ENVB0.1820-0.0181-9.05
AAPL141.663.39002.45
GOOG2 370.76117.07005.19
MSFT267.708.84003.41
XOM86.901.69001.98
WFC40.762.86007.55
JNJ182.292.63001.46
FB196.640.99000.51
GE67.083.01004.70
JPM117.323.40002.98
Financial StrengthValueIndustryS&P 500US Markets
10.40
10.80
0.00
0.01
-3 977.80
Leverage Ratio 1.30
ProfitabilityValueIndustryS&P 500US Markets
238.70
84.00
84.00
-18.50
41.77
RevenueValueIndustryS&P 500US Markets
0.00
0.00
-
-
Earnings HistoryEstimateReportedSurprise %
Q01 2022--0.11-
Q04 2021--0.14-
Q01 2021--0.20-
Q03 2020--0.80-
Q01 2020--2.40-
Q03 2019-0.00-
Q02 2019--0.03-
Q01 2019--0.04-
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date12th Aug 2022
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume1.34M
Shares Outstanding52.68K
Shares Float51.32M
Trades Count2.80K
Dollar Volume269.88K
Avg. Volume1.36M
Avg. Weekly Volume1.10M
Avg. Monthly Volume1.06M
Avg. Quarterly Volume1.91M

Enveric Biosciences Inc. (NASDAQ: ENVB) stock closed at 0.182 per share at the end of the most recent trading day (a -9.05% change compared to the prior day closing price) with a volume of 1.34M shares and market capitalization of 9.59M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 3 people. Enveric Biosciences Inc. CEO is David I. Johnson.

The one-year performance of Enveric Biosciences Inc. stock is -90.52%, while year-to-date (YTD) performance is -80.43%. ENVB stock has a five-year performance of %. Its 52-week range is between 0.17 and 3.74, which gives ENVB stock a 52-week price range ratio of 0.34%

Enveric Biosciences Inc. currently has a PE ratio of -0.10, a price-to-book (PB) ratio of 0.40, a price-to-sale (PS) ratio of -1.23, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -177.79%, a ROC of -229.72% and a ROE of -237.17%. The company’s profit margin is 41.77%, its EBITDA margin is 84.00%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Enveric Biosciences Inc., there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Enveric Biosciences Inc.’s next earnings report date is 12th Aug 2022.

The consensus rating of Wall Street analysts for Enveric Biosciences Inc. is Moderate Buy (1.67), with a target price of $0.65, which is +257.14% compared to the current price. The earnings rating for Enveric Biosciences Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Enveric Biosciences Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Enveric Biosciences Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 13.39, ATR14 : 0.02, CCI20 : -109.57, Chaikin Money Flow : -0.33, MACD : -0.01, Money Flow Index : 41.31, ROC : -16.36, RSI : 38.51, STOCH (14,3) : 6.92, STOCH RSI : 0.05, UO : 35.10, Williams %R : -93.08), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Enveric Biosciences Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (66.67 %)
1 (50.00 %)
1 (50.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
1 (33.33 %)
1 (50.00 %)
1 (50.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
1.67
Moderate Buy
2.00
Moderate Buy
2.00

Enveric Biosciences Inc.

Enveric Biosciences Inc is a patient-centric biotechnology company focused on developing new-generation, naturally occurring chemical compounds, such as cannabinoids to improve the lives of those who are adversely affected by the side effects of cancer treatments. Its product in the pipeline includes Glioblastoma Multiforme (GBM); Radiation Dermatitis and Chemotherapy-Induced Peripheral Neuropathy (CIPN).

CEO: David I. Johnson

Telephone: +1 239 302-1707

Address: 4851 Tamiami Trail N, Naples 34103, FL, US

Number of employees: 3

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

58%42%

Bearish Bullish

56%44%

Bearish Bullish

58%42%

News

Stocktwits